12-May-2025 3:01 PM CST - Business Wire Arcturus Therapeutics Announces First Quarter 2025 Financial Update and Pipeline Progress $ARCT #ClinicalTrial--Arcturus Therapeutics Holdings Inc. (the Company, Arcturus, Nasdaq: ARCT), a commercial messenger RNA medicines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases, today announced its financial results for the first quarter ended March 31, 2025, and provided corporate updates. We are delighted with enrollment in our cystic fibrosis (CF) program, and the company is working diligently to p
22-Apr-2025 3:01 PM CST - Business Wire Arcturus Therapeutics to Report First Quarter Financial Results and Provide Corporate Update on May 12, 2025 $ARCT #ClinicalTrial--Arcturus Therapeutics Holdings Inc. (the Company, Arcturus, Nasdaq: ARCT), a commercial messenger RNA medicines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases, today announced that it will release its financial results for the quarter ended March 31, 2025 after the market close on Monday, May 12 and will also host a conference call and webcast at 4:30 pm Eastern Time on May 12, 2025.
6-Mar-2025 3:01 PM CST - Business Wire Arcturus Therapeutics Announces Fourth Quarter and Fiscal Year 2024 Financial Update and Pipeline Progress $ARCT #ClinicalTrial--Arcturus Therapeutics Holdings Inc. (the Company, Arcturus, Nasdaq: ARCT), a commercial messenger RNA medicines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases, today announced its financial results for the fourth quarter ended December 31, 2024, and provided corporate updates. We continue to progress our flagship rare disease programs and look forward to sharing meaningful Phase 2 in
24-Feb-2025 3:01 PM CST - Business Wire Arcturus Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Corporate Update on March 6, 2025 $ARCT #ClinicalTrial--Arcturus Therapeutics Holdings Inc. (the Company, Arcturus, Nasdaq: ARCT), a commercial messenger RNA medicines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases, today announced that it will release its financial results for the quarter and year ended December 31, 2024 after the market close on Thursday, March 6 and will also host a conference call and webcast at 4:30 p.m. Eastern Time
30-Jan-2025 3:01 PM CST - Business Wire Arcturus Therapeutics to Present at Guggenheim Securities SMID Cap Biotech Conference $ARCT #ClinicalTrial--Arcturus Therapeutics Holdings Inc. (the Company, Arcturus, Nasdaq: ARCT), a commercial messenger RNA medicines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases, today announced that the Company will participate at a fireside chat hosted by Guggenheim Securities SMID Cap Biotech Conference in New York, on Thursday, February 6, 2025, at 10:30 a.m. Eastern Time. Webcast link can be found
16-Dec-2024 3:01 PM CST - Business Wire Arcturus Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference $ARCT #ClinicalTrial--Arcturus Therapeutics Holdings Inc. (the Company, Arcturus, Nasdaq: ARCT), a commercial messenger RNA medicines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases, today announced that Joseph Payne, President & Chief Executive Officer, will present at the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco, on Wednesday, January 15, 2025, at 9:45 a.m. Pacific Time. A webcas
26-Nov-2024 3:01 PM CST - Business Wire Arcturus Therapeutics to Attend Upcoming Investor Conferences $ARCT #ClinicalTrial--Arcturus Therapeutics Holdings Inc. (the Company, Arcturus, Nasdaq: ARCT), a commercial messenger RNA medicines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases, today announced that the Company will participate in the following investor conferences: Piper Sandler 36th Annual Healthcare Conference (Fireside Chat) Tuesday, December 3, 2024 (4:30 p.m. ET) Citis 2024 Global Healthcare Con
18-Nov-2024 7:00 PM CST - Business Wire Arcturus Therapeutics to Present at Jefferies London Healthcare Conference $ARCT #ClinicalTrial--Arcturus Therapeutics Holdings Inc. (the Company, Arcturus, Nasdaq: ARCT), a commercial messenger RNA medicines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases, today announced that the Company will present at Jefferies London Healthcare Conference in London, on Wednesday, November 20, 2024, at 9:30 am GMT. A webcast and replay of the presentation will be available on the Investor Rela
7-Nov-2024 3:01 PM CST - Business Wire Arcturus Therapeutics Announces Third Quarter 2024 Financial Update and Pipeline Progress $ARCT #ClinicalTrial--Arcturus Therapeutics Holdings Inc. (the Company, Arcturus, Nasdaq: ARCT), a commercial messenger RNA medicines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases, today announced its financial results for the third quarter ended September 30, 2024, and provided corporate updates. I am thrilled about the approval of KOSTAIVE for the COVID-19 JN.1 strain in Japan and for the continued su
12-May-2025 3:01 PM CST - Business Wire Arcturus Therapeutics Announces First Quarter 2025 Financial Update and Pipeline Progress $ARCT #ClinicalTrial--Arcturus Therapeutics Holdings Inc. (the Company, Arcturus, Nasdaq: ARCT), a commercial messenger RNA medicines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases, today announced its financial results for the first quarter ended March 31, 2025, and provided corporate updates. We are delighted with enrollment in our cystic fibrosis (CF) program, and the company is working diligently to p
22-Apr-2025 3:01 PM CST - Business Wire Arcturus Therapeutics to Report First Quarter Financial Results and Provide Corporate Update on May 12, 2025 $ARCT #ClinicalTrial--Arcturus Therapeutics Holdings Inc. (the Company, Arcturus, Nasdaq: ARCT), a commercial messenger RNA medicines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases, today announced that it will release its financial results for the quarter ended March 31, 2025 after the market close on Monday, May 12 and will also host a conference call and webcast at 4:30 pm Eastern Time on May 12, 2025.
6-Mar-2025 3:01 PM CST - Business Wire Arcturus Therapeutics Announces Fourth Quarter and Fiscal Year 2024 Financial Update and Pipeline Progress $ARCT #ClinicalTrial--Arcturus Therapeutics Holdings Inc. (the Company, Arcturus, Nasdaq: ARCT), a commercial messenger RNA medicines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases, today announced its financial results for the fourth quarter ended December 31, 2024, and provided corporate updates. We continue to progress our flagship rare disease programs and look forward to sharing meaningful Phase 2 in
24-Feb-2025 3:01 PM CST - Business Wire Arcturus Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Corporate Update on March 6, 2025 $ARCT #ClinicalTrial--Arcturus Therapeutics Holdings Inc. (the Company, Arcturus, Nasdaq: ARCT), a commercial messenger RNA medicines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases, today announced that it will release its financial results for the quarter and year ended December 31, 2024 after the market close on Thursday, March 6 and will also host a conference call and webcast at 4:30 p.m. Eastern Time
30-Jan-2025 3:01 PM CST - Business Wire Arcturus Therapeutics to Present at Guggenheim Securities SMID Cap Biotech Conference $ARCT #ClinicalTrial--Arcturus Therapeutics Holdings Inc. (the Company, Arcturus, Nasdaq: ARCT), a commercial messenger RNA medicines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases, today announced that the Company will participate at a fireside chat hosted by Guggenheim Securities SMID Cap Biotech Conference in New York, on Thursday, February 6, 2025, at 10:30 a.m. Eastern Time. Webcast link can be found
16-Dec-2024 3:01 PM CST - Business Wire Arcturus Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference $ARCT #ClinicalTrial--Arcturus Therapeutics Holdings Inc. (the Company, Arcturus, Nasdaq: ARCT), a commercial messenger RNA medicines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases, today announced that Joseph Payne, President & Chief Executive Officer, will present at the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco, on Wednesday, January 15, 2025, at 9:45 a.m. Pacific Time. A webcas
26-Nov-2024 3:01 PM CST - Business Wire Arcturus Therapeutics to Attend Upcoming Investor Conferences $ARCT #ClinicalTrial--Arcturus Therapeutics Holdings Inc. (the Company, Arcturus, Nasdaq: ARCT), a commercial messenger RNA medicines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases, today announced that the Company will participate in the following investor conferences: Piper Sandler 36th Annual Healthcare Conference (Fireside Chat) Tuesday, December 3, 2024 (4:30 p.m. ET) Citis 2024 Global Healthcare Con
18-Nov-2024 7:00 PM CST - Business Wire Arcturus Therapeutics to Present at Jefferies London Healthcare Conference $ARCT #ClinicalTrial--Arcturus Therapeutics Holdings Inc. (the Company, Arcturus, Nasdaq: ARCT), a commercial messenger RNA medicines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases, today announced that the Company will present at Jefferies London Healthcare Conference in London, on Wednesday, November 20, 2024, at 9:30 am GMT. A webcast and replay of the presentation will be available on the Investor Rela
7-Nov-2024 3:01 PM CST - Business Wire Arcturus Therapeutics Announces Third Quarter 2024 Financial Update and Pipeline Progress $ARCT #ClinicalTrial--Arcturus Therapeutics Holdings Inc. (the Company, Arcturus, Nasdaq: ARCT), a commercial messenger RNA medicines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases, today announced its financial results for the third quarter ended September 30, 2024, and provided corporate updates. I am thrilled about the approval of KOSTAIVE for the COVID-19 JN.1 strain in Japan and for the continued su
